Clifford J. Bailey, PhD, FRCP, FRCPath

Professor of Clinical Science

School of Life & Health Sciences 
Aston University
Aston Triangle
Birmingham B4 7ET

Email: c.j.bailey@aston.ac.uk 
telephone: +44 (0) 121 204 3898
fax: +44 (0) 121 204 3892

Member of the Pharmacy and Biology Teaching Programmes

Research Group

Cell and Tissue Biomedical Research

Research Centre
Aston Research Centre for Healthy Ageing

Aston Research centre in CHildren and Young people's health(ARCHY)                

I contribute to lectures and practical classes in physiology and lectures and workshops in clinical pharmacy. 

Professor and Head of Diabetes Research, Aston University
Formerly Reader and Senior Lecturer in Pharmacology, and Lecturer in Physiology, Aston University

1998 FRCP, Fellowship, Royal College of Physicians, Edinburgh 
1996 FRCPath, Fellowship, Royal College of Pathologists

Diabetes Research at Aston University studies the regulation of nutrient metabolism, the pathogenesis of diabetes mellitus and obesity, and the development of new therapies. Specific interests include:

  • Pathogenesis and interventional approaches against insulin resistance
  • Discovery and development of agents to treat diabetes and obesity
  • Islet transplantation and therapeutic use of genetically modified insulin-releasing cells
  • Study design and evaluation of therapies for diabetes and obesity
  • British Endocrine Society
  • British Pharmacological Society
  • Diabetes UK, Medical and Scientific Section
  • European Association for the Study of Diabetes
  • Founding member of EASD Islet Study Group
  • International Society of Diabetes & Vascular Disease
  • Royal College of Pathologists
  • Royal College of Physicians, Edinburgh


  • Bailey CJ. Metformin.  In  Therapy for Diabetes Mellitus and Related Disorders, 6th edn.  Umpierrez GE, ed.  American Diabetes Association, Alexandria VA, 2014, pp341-358.

  • Home P, Riddle M, Cefalu WT, Bailey CJ,  Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I.  Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 2014, 37, 1499-508.

  • Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ,  McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review.  JAMA 2014, 312, 2668-75.  
  • Rana KS, Arif  M, Hill EJ, Aldred  S, Nagel DA, Nevill A, Randeva HS, Bailey CJ,  Bellary S, Brown JE.  Plasma irisin levels predict telomere length in healthy adults.  Age 2014, 36, 995-1001.

  • Ahren B, Gautier JF, Berria R, Aronson R, Bailey CJ. Pronounced reduction of glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obesity Metab 15, in press 2014. Doi 10.111/dom.12290

  • Qureshi KM, Lee J, Paget MB, Bailey CJ, Curnow SJ, Murray HE, Downing R. Low gravity rotational culture and the    integration of immunomodulatory stem cells reduce human islet allo-reactivity. Cell Transplant  2014 in press


  • Bailey CJInterpreting adverse signals in diabetes drug development programs. Diabetes Care 36, 1-9, 2013.
  • Bailey CJTreatment with metformin.  In  The Metabolic Syndrome, Beck-Nielsen H (ed). Springer-Verlag, Vienna, pp 99-116, 2013.
  • Tahrani AA, Barnett AH,Bailey CJSGLT inhibitors in management of diabetes.  Lancet  Diabetes Endocrinology 1, 140-151, 2013
  • ,Bailey CJ.Aschner P. Del Prato S, LaSalle J, Ji L, Matthaei S.  Individualised glycaemic targets and pharmacotherapy in type 2 diabetes. Diabetes Vasc Dis Res 10, 397-409, 2013.
  • Fouqueray P, Pirags V, Inzucchi SE,Bailey CJ,  Schernthaner G, Diamont M, Lebovitz HE.  The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.  Diabetes Care  36, 565-8, 2013.
  • Bailey CJ,  Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF.  Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.  BMC Medicine 2013, 11:43 doi:10.1186/1741-7015-11-43.  Open access.                 http://www.biomedcentral.com/1741-7015/11/43
  • Paget MB, Murray HE,Bailey CJDowning R.  Pre-transplant signal induction for vascularization in human islets.  Diabetes Vasc Dis Res 10, 536-45, 2013


  • Bailey CJ.  Could FFAR1 assist insulin secretion in type 2 diabetes? Lancet 379,1370-1,2012
  • Tahrani A, Bailey CJ, Barnett AH. Insulin degludec:new longer-acting insulin. Lancet  379,1465-7, 2012.
  • Bailey CJ, Metformin add-on to insulin in type 2 diabetes.Nature Endocr Rev 8, 449-450,  2012.
  • Day C, Bailey CJ.  Obesity in the aetiology of type 2 diabetes. In Chronic non-communicable diseases, Purcell H (ed). National Services for Health Improvement, Dartford,pp 27-43, 2012.
  • Bailey CJ, Day C. Managing glycaemia:recently introduced and future therapies. In Type 2 diabetes, Barnett AH, ed. Oxford University Press, Oxford, pp117-131, 2012.
  • Bailey CJ, Day C, Campbell IW, Schindler C. Glycaemic control and cardiovascular outcome trials in type 2 diabetes. Br J Diabetes Vasc Dis 12, 161-164, 2012.
  • Bailey CJ, Day C. Diabetes therapies in renal impairment. Br J Diabetes Vasc Dis 12, 167-171, 2012.
  • Gao D, Pararasa C, Dunston CR, Bailey CJ, Griffiths HR. Palmitate promotes monocyte atherogenicity via de novo ceramides synthesis. Free Radical Biol Med 53, 796-806,2012.
  • Bailey CJ, Iqbal N, T'joen, List JF.  Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomised-controlled trial of low-dose range. Diabetes Obesity Metab 14, 951-9,2012.


  • Bailey CJ.  Renal glucose reabsporption inhibitors to treat diabetes. Trends Pharmacol Sci 32, 63-71, 2011.
  • Tahrani A, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment.  Lancet  378, 182-97, 2011.  doi: 10.1016/S0140-6736(11)60207-9.
  • Qureshi K M, Oliver RJ, Paget MB, Murray HE, Bailey CJ, Downing R. Human amniotic epithelial cells induce localized cell-mediated immune-privilege in vitro: implications for pancreatic islet transplantation.  Cell Transplantation 20, 523-34,  2011.
  • Ramachandran S, Saraf S, Shetty C, Capps N, Bailey C.  Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Ann Clin Biochem   48, 75-78, 2011.
  • Lipska KJ, Bailey CJ, Inzucchi SE.  Use of metformin in the setting of mild-moderate renal insufficiency.  Diabetes Care  34, 1431-7, 2011.
  • Paget MB, Murray HE, Paget MB, Bailey CJ, Flatt PR, Downing R.  A thiazolidinedione increases insulin secretion from clonal beta cells and enhances human umbilical vein endothelial cell proliferation in static and rotational culture. Diabetes Obesity Metab 13, 662-8, 2011.
  • Bailey CJ, Kodack M.  Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 65, 314-22, 2011.
  • Bailey CJ.  The challenge of managing coexistent type 2 diabetes with obesity.  BMJ 2011 doi: 10.1136/bmj.d1996.
  • Day C, Bailey CJ.  Obesity in the pathogenesis of type 2 diabetes.  Br J Diabetes Vasc Dis 11, 61-65, 2011.
  • Bailey CJ, Davies MJ. Pharmacological therapy of hyperglycaemia in type 2 diabetes mellitus.  In Oxford Textbook of Endocrinology and Diabetes, 2nd edn, WassJAH, Stewart PM (eds). Oxford Univ Pr, Oxford, 2011, pp1779-95.


  • Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet  375, 2223-33, 2010.
  • Irwin N, McKinney JM, Bailey CJ, Flatt PR, McClenaghan NH.  Effects of metformin on pancreatic beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas.  Diabetes Obesity Metab 12, 1066-71, 2010.
  • McKinney JM, Irwin N, Flatt PR, Bailey CJ, McClenaghan NH.  Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal B-cells.  Biol Chem 391, 1451-9, 2010.
  • Del Prato S, Bailey CJ, La Salle J.  Tailoring treatment to the individual in type 2 diabetes.  Practical guidance from the Global partnership for Effective Diabetes Management.  Int J Clin Pract 64, 295-304, 2010
  • Bailey CJ, Day C. Hypoglycaemia: a limiting factor.  Br J Diabetes Vasc Dis  10, 2-4, 2010.
  • Bergenstal RM, Bailey CJ, Kendall DM. Therapeutic decision-making in type 2 diabetes: assessing the relative risks and benefits of glucose lowering medicines.  Am J Med 123, 374-83e, 2010.
  • Bailey CJ.  New drugs for type 2 diabetes. In Hot topics in diabetes, 3rd edn, Vora J, ed. Synergy, London, pp 73-80, 2010
  • Bailey CJ, Barnett AH. Inhaled insulin: new formulation, new trial. Lancet 375, 2199-2201, 2010.
  • Bailey CJ, Green BD, Flatt PR.  Fixed-dose combination therapy for type 2 diabetes: :sitagliptin plus pioglitazone.  Expert Opinion Investig Drugs 19, 1017-25, 2010.
  • Bailey CJ, Krentz AJ.  Treatment of type 2 diabetes. In Textbook of Diabetes, 4th edn, Holt RIG et al  (eds).  Blackwell, Oxford, 2010, pp 452-77.
  • Bailey CJ.  Future pharmacotherapy of diabetes.   In Textbook of Diabetes, 4th edn, Holt RIG et al  (eds).  Blackwell, Oxford, 2010, pp 1017-44.
  • Green BD, Bailey CJ, Flatt PR.  Gliptin therapies for inhibiting dipeptidyl peptidase-4 in type 2 diabetes.  European Endocrinol 6, 19-25, 2010.
  • Holt RIG, Barnett AH, Bailey CJ.  Bromocriptine: old drug, new formulation and new indication.  Diabetes Obesity Metab  12: 1048-57, 2010.
  • Barnett  A, Bailey C, Evans M, Haslam D, Hicks D, Hughes E.  Implementing the NICE guideline for type 2 diabetes: weight gain and hypoglycaemia.  Diabetes Primary Care 12, 54-63, 2010.
  • Bailey CJ, Day C.  SGLT2 inhibitors: glucuretic treatment for type 2 diabetes.  Br J Diabetes Vasc Dis  10,193-9,2010



  • Bailey CJ, Day C.  Fixed-dose single tablet antidiabetic combinations.  Diabetes Obesity Metab 11, 527-33, 2009.
  • Flatt PR, Bailey CJ, Green BD. Recent advances in antidiabetic therapies targeting the enteroinsular axis. Curr Drug Metab 10, 125-37, 2009.
  • Day C, Bailey CJ. Which weight loss diet? Br J Diabetes Vasc Dis 9, 43, 2009
  • Flatt PR,Day C, Bailey CJ.  Bariatric surgery to treat diabesity.  Br J Diab Vasc Dis  9, 103-7, 2009.
  • Day C, Bailey CJ.  HbA1c  -  changing units.  Br J Diab Vasc Dis  9, 134-6, 2009.
  • Bailey CJ, Blonde L, Del Prato S, Leiter LA, Nesto R.  What are the practical implications for treating diabetes in light of recent evidence?  Updated recommendations from the Global partnership for Effective Diabetes Management.   Diabetes Vasc Dis Res 6, 283-7, 2009.
  • Murray HE, Paget MB, Bailey CJ, Downing R.  Sustained insulin secretory response in human islets co-cultured with pancreatic duct-derived epithelial cells within a rotational cell culture system. Diabetologia 52, 477-85, 2009.
  • Kerr BD, Irwin N, O’Harte FPM, Bailey CJ, Flatt PR, Gault VA. Novel fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with prolonged antihyperglycaemic properties.  Biochem Pharmacol 78, 1008-16, 2009 
  • Naujok O, Francini F, Picton S, Bailey CJ, Lenzen S, Jorns A. Changes in gene expression and morphology of mouse. embryonic stem cells upon differentiation into insulin-producing cells in vitro and in vivo. Diab Metab Res 25, 463-76, 2009.
  • Tan BK, Chen J, Brown J, Adya R, Ramanjaneya M, Menon V, Bailey CJ, Lehnert H, Randeva HS.  In vivo and ex vivo regulation of visfatin production by leptin in human and murine adipose tissue: role of MAPK and PI3-K signaling pathways.  Endocrinology 150, 3530-9, 2009.
  • Gao D, Griffiths HR, Bailey CJ.  Oleate protects against palmitate-induced insulin resistance in L6 myotubes.  Br J  Nutrition 102, 1557-63, 2009.
  • Gao D, Bailey CJ, Griffiths HR. Metabolic memory effect of the saturated fatty acid palmitate in monocytes.  Biochem Biophys Res Comm 388: 278-82, 2009.


  • Bailey CJ, Barnett AH, Petrie JR.  Value of glycaemic control in diabetes. Lancet 371, 116, 2008.
  • Bailey CJ, Day C.  Managing glycaemia: recently introduced and future therapies.  In Type 2 diabetes, Barnett AH, ed. Oxford University Press, Oxford, pp75-86, 2008.
  • Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.   Frontiers in Bioscience 13, 3648-3660, 2008.
  • Bailey CJ.  Metformin: effects on micro and macrovascular complications in type 2 diabetes.  Cardiovasc Drug Ther 22, 215-224, 2008.
  • Krentz AJ, Patel MB, Bailey CJ.  New drugs for type 2 diabetes mellitus: what is their place in therapy?  Drugs 68, 2131-62, 2008.
  • Bailey CJ.  New drug therapies for the treatment of diabetes. In Hot topics in diabetes, Vora J, ed. Synergy, London, pp91-100, 2008.
  • Cooper MB, Al Majali K, Bailey CJ, Betteridge DJ.  Reduced postprandial proinsulinaemia and 32–33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. Clin Endocrinol 68: 738-46, 2008.
  • Bailey CJ, Wilcock C, Scarpello JHB.  Metformin and the intestine. Diabetologia 51, 1552-3, 2008.


  • Bailey CJ, Alberti KGMM.  Cardio-diabetes alliances. Diab Vasc Dis Res 4, 5-6, 2007.
  • Paget M, Murray H, Bailey CJ, Downing R.  Human islet isolation: semi-automated and manual methods.  Diab Vasc Dis Res 4, 7-12, 2007.
  • Bailey CJ, Barnett AH.  Why is Exubera being withdrawn?  BMJ 335, 1156, 2007.
  • Bailey CJ, Barnett AH, Day C.  Exubera expires.  Brit J Diab vasc Dis 6, 255-256, 2007.
  • Bailey CJ.  Treating insulin resistance: future prospects.  Diab Vasc Dis Res 4, 20-31, 2007.
  • Bailey CJ.  Learning from tesaglitazar. Diab Vasc Dis Res 4, 161-2, 2007.
  • Alberti KGMM, Bailey CJ, Blonde L, Felton AM, Zimmet P. Partnering with governments and other institutions: driving change in diabetes care.  Int J Clin Pract 61, suppl 157, 38-46, 2007.
  • Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW.  A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes.  Diabetic Med 24, 618-625, 2007.
  • O’Harte FP, Hunter K, Gault VA, Irwin N, Green BD, Harriott P, Bailey CJ, Flatt PR.  Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. Am J Physiol Endocrinol Metab292, E1674-82, 2007.


  • Bailey CJ.  Fenofibrate and cardiovascular risk: a synopsis and commentary on FIELD.  Diabetic med  23, 109-112, 2006.
  • Day C, Bailey CJ.  Preclinical and cinical methods for evaluating antidiabetic activity of plants.  Medicine for Modern Times.  Soumyanath A, ed. Taylor and Francis, pp83-98, 2006.
  • Bailey CJ, Day C.  Increasing choice to treat obesity.  Brit J Diab Vasc Dis 6, 101, 2006.
  • Day C, Bailey CJ.  Pharmacological approaches to reduce adiposity. Brit J Diab Vasc Dis 6, 121-126, 2006.
  • Bailey CJ, Day C, Campbell IW.  A consensus algorithm for treating hyperglycaemia in type 2 diabetes.  Brit J Diab vasc Dis 6, 147-148, 2006.
  • Nattrass M, Bailey CJ.  New oral agents for type 2 diabetes.  In Diabetes, Barnett AH, ed. Elsevier, Philadelphia, pp209-221, 2006.
  • Bailey CJ.  Early and intensive treatment: glycaemic control in type 2 diabetes.  Diab Vasc Dis Res 3, 145-146, 2006.
  • Green BD, Flatt PR, Bailey CJ.  Inhibition of dipeptidyl peptidase IV activity as a therapy of type 2 diabetes.  Expert Opin Emerging Drugs 11, 525-539, 2006.
  • Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes.  Diab VascDis Res 3, 159-165, 2006.
  • Coletta DK, Bates SH, Jones RB, Bailey CJ. The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data.  Diab Vasc Dis Res 3, 186-188, 2006.
  • Richardson DK, Jones RB, Bailey CJ.  The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes. Horm Metab Res 38, 727-731,2006.


  • Krentz AJ, Bailey CJ.  Oral antidiabetic agents:  current role in type 2 diabetes mellitus.  Drugs  65, 385-411, 2005.
  • Bailey CJ, Day C.  New pharmacological approaches to obesity.  Obesity in Practice, 1, 2-5, 2005.
  • Bailey CJ.  Effect of management of the metabolic syndrome. J Thromb Haem, 3, 1083-1085, 2005.
  • Bailey CJ.  Treating insulin resistance in type 2 diabetes: metformin and thiazolidinediones.  Diab Obesity Metab 7,  675-691, 2005.
  • Bailey CJ.  Whence and whither the fixed-dose combination?  Diab Vasc Dis Res 2, 51-53, 2005.
  • Bailey CJ, Del Prato S, Eddy D, Zinman B.   Earlier intervention to control glucose homeostasis in type 2 diabetes.  Int J Clin Pract  59, 1309-1316, 2005.
  • Bailey CJ.  Overview of new and developing pharmacological treatments.  Eur Heart J 26, s7, D23-D26,2005.
  • Bailey CJ.  Drugs on the horizon for diabesity. Current Diabetes Reports 5, 353-359, 2005.
  • Hartell N, Archer H, Bailey CJ.  Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B.  Biochem Pharmacol 69, 781-790, 2005.
  • Green B, Irwin N, Gault VA, Bailey CJ, , O’Harte FPM, Flatt PR.  Chronic treatment with exendin (9-39) amide indicates a minor role for endogenous glucagons-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.  J Endocrinol 185, 307-317, 2005.
  • Irwin N, Gault VA, Green B, Greer B, Harriott P, Bailey CJ, Flatt PR, O’Harte FPM.  Degradation, insulin secretion and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.  J Med Chem. 48, 1244-1250, 2005  
  • Gault VA, Irwin N, Green B, McCluskey JT, Greer B, Bailey CJ, Harriott P, O’Harte FPM, Flatt PR.  Chemical ablation of gastric inhibitory polypeptide receptor action by daily (pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.  Diabetes 54, 2436-46, 2005.
  • Irwin N, Green B, Mooney MH, Greer B, Harriott P, Bailey CJ, Gault VA, O’Harte FPM, Flatt PR.  A novel long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.  J Pharm Exp Ther 314, 1187-1192, 2005.
  • Irwin N, Gault VA, Green B, Greer B, Harriott P, Bailey CJ, Flatt PR, O’Harte FPM.  Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent polypeptide (GIP): N-AcGIP(Lys PAL16) and N-AcGIP(Lys PAL37).  Biol Chem 386, 679-687, 2005.
  • Bailey CJ, Bagdonas A, Rubes J, MeMorn SO, Donaldson J, Biswas N, Stewart MW.  Rosiglitazone/metformin fixed dose combination compared with up-titrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel group study.  Clin Therapeutics 27, 1548-1561, 2005.


  • Feher MD, Bailey CJ.  Reclassifying insulins.  Brit J Diab Vasc Dis 4, 39-42, 2004.
  • Bailey CJ, Day C.  Metformin: its botanical background.  Pract Diab Int 21, 115-117, 2004.
  • Bailey CJ.  New drugs for the treatment of diabetes mellitus. In International Textbook of Diabetes Mellitus, 3rd edn.  DeFronzo RA, Ferrannini E, Keen H, Zimmet P, eds.  Wiley, Chichester, 2004, pp 951-979.
  • Bailey CJ.  Metformin.  In  Therapy for Diabetes Mellitus and Related Disorders, 4th edn.  Lebovitz HE, ed.  American Diabetes Association, Alexandria VA, 2004, 176-191.
  • Lintern MC, Cooke L, Scriven H, Bailey CJ, Smith ME.  Altered activity of cholinergic enzymes in muscles of the obese-diabetic (ob/ob) mouse.  In Cholinergic mechanisms:  Function and dysfunction.  Silmay I, Song H, Anglisti L, Michaelson D, Fisher A, eds.  Taylor and Francis, London, 2004, pp 623-626.
  • Bailey CJ, Day C.  Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.  Int J Clin Pract  58, 867-876, 2004.
  • Green B, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O’Harte FPM. Flatt PR.  N-terminal His7 modification of glucagon-like peptide-1 (7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihypeglycaemic activity.  J Endocrinol 180, 379-388, 2004.
  • Green B, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O’Harte FPM.  Lys9 for Glu9 substitution in glucagons-like peptide-1 (7-36) amide confers dipeptidyl peptidase resistance with cellular and metabolic actions similar to those of established antagonists of glucagons-like peptide-1 (9-36)amide and exendin 9-39.  Metabolism 53, 252-259, 2004.
  • Bailey CJ, Turner SL. Glucosamine-induced insulin resistance in cultured muscle cells.  Diabetes, Obesity, Metabolism 6, 293-298, 2004.


  • Bailey CJ, Day C. Antidiabetic drugs.  Brit J Cardiol 10, 128-136, 2003.
  • Bailey CJ.  Oral antidiabetic drugs.  Encyclopedic Reference of Molecular Pharmacology.  Offermanns S, Rosenthal W (eds).  Springer-Verlag, Heidelberg, 2003, pp 688-695. 
  • Bailey CJ, Flatt PR.  Animal syndromes resembling type 2 diabetes.  In Textbook of Diabetes, 3rd edn, Pickup JC, Williams G (eds).  Blackwell, Oxford, 2003, pp 25.1-25.30.
  • Bailey CJ.  New approaches to the pharmacotherapy of diabetes.   In Textbook of Diabetes, 3rd edn, Pickup JC, Williams G (eds).  Blackwell, Oxford, 2003, pp 73.1 –73.21.
  • Day C, Archer H, Bailey CJ.  Recent advances in insulin therapy.  Brit J Cardiol 10, 379-383, 2003.
  • Bailey CJ, Day C, Krentz AJ.  Nice timing for glitazones.  Brit J Diab Vasc Dis 3, 366-367, 2003.
  • Carter D, Howlett HCS, Wiernsperger NF, Bailey CJ.  Differential effects of metformin on bile salt absorption from jejunum and ileum.  Diabetes, Obesity, Metabolism 5, 120-125, 2003.
  • Gault VA, Flatt PR, Harriott P, Mooney MH, Bailey CJ, O’Harte FPM.  Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide.  J Endocrinol 176, 133-141, 2003.
  • Green B, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O’Harte FPM.  Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 (7-36 amide) have preserved biological activities in vitroconferring improved glucose-lowering action in vivo.  J Mol Endocrinol 31, 529-540, 2003.
  • Green B, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O’Harte FPM. Metabolic stability, receptor binding, camp generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.  Biol Chem 384, 1543-1551,2003.


  • Bailey CJ, Campbell IW.  United Kingdom Prospective Diabetes Study:  implications for metformin.  Brit J Cardiol 9, 115-119, 2002.
  • Bailey CJ, Day C.  Future therapies.  Curr Med Res Opin 18, suppl 1, s82-s88, 2002.
  • Bailey CJ.  Future trends in diabetes care: treatment.  In Oxford textbook of endocrinology and diabetes.  Wass JAH, Shalet SM (eds).  Oxford University Press, Oxford 2002, ch 12.17.2 pp 1849-1856. 
  • Bailey CJ, Campbell IW.  NICE guidelines: management of blood glucose in type 2 diabetes.  Brit J Diab Vasc Dis 2, 390-391, 2002.  
  • Day C, Bailey CJ.  Sibutramine update.  Brit J Diab Vasc Dis 2, 392-397,     2002.
  • Eason RC, Archer HE, Akhtar S, Bailey CJ.  Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice.  Diabetes, Obesity, Metabolism 4, 29-35, 2002.
  • Bates SH, Gardiner JV, Jones RB, Bloom SR, Bailey CJ.  Acute stimulation of glucose uptake by leptin in L6 muscle cells.  Horm Metab Res 34, 111-115, 2002.
  • Carter D, Howlett HCS, Wiernsperger NF, Bailey CJ.  Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells.  Diabetes, Obesity, Metabolism 4, 424-27, 2002.
  • Goldstone AP, Howard JK, Lord GM, Ghatei MA, Gardiner JV, Wang ZL, Wang RM, Girgis SI, Bailey CJ, Bloom SR.  Leptin prevents the fall in plasma osteocalcin during starvation in male mice.  Biochem Biophys Res Comm  295, 475-81, 2002.
  • Gault VA, Flatt PR, Bailey CJ, Harriott P, Greer B, Mooney MH, O’Harte FPM.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.  Biochem J 367, 913-20, 2002.
  • O’Harte FPM, Gault VA, Parker JC, Harriott P, Mooney MH, Bailey CJ, Flatt PR.   Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.  Diabetologia 45,1281-91,2002.


  • Bailey CJ. New approaches to the management of type 2 diabetes. In The  Essence of Type 2 Diabetes, Barnett AH (ed). Medical Education Partnership, London, 2001, pp20-24.
  • Bailey CJ, Day C.  Thiazolidinediones today.  Brit J Diab Vasc Dis 1, 7-13, 2001.
  • Bailey CJ.  The diabetes prevention program: headline results. Brit J Diab Vasc Dis 1, 62-64, 2001.
  • Coleman MD, Eason RC, Bailey CJ.  The therapeutic use of lipoic acid in diabetes: a current perspective.  Env Tox Pharmacol 10, 167-172, 2001.
  • Bailey CJ.  New pharmacologic agents for diabetes.  Curr Diab Reps 1, 119-126, 2001.
  • Campbell IW, Bailey CJ.  New approaches to glycaemic control in type 2 diabetes.  Mod Diab Management  2, 6-10, 2001.
  • Bailey CJ.  Going beyond glycaemic control to address insulin resistance.  Brit J Cardiol 8, suppl 4, S3-S5, 2001.
  • Bailey CJ, Day C, Krentz AJ.  Glitazone guidelines: clarity or confusion?  Prescriber  66-69,2001
  • Bailey CJ, Turner SL, Bates SH, Jones RB. Sibutramine metabolites increase glucose transport by cultured rat muscle cells. Int J Obesity 25, 1-8, 2001.
  • Davies EL, Abdel-Wahab YHA, Flatt PR, Bailey CJ.  Functional enhancement of electrofusion-derived BRIN-BD11 insulin secreting cells after implantation into diabetic mice.  Int J Exp Diab Res 2, 29-36, 2001.
  • Evans AAL, Tunnicliffe G, Knights P, Bailey CJ, Smith ME.  Delta opioid receptors mediate glucose uptake in skeletal muscles of lean and obese-diabetic (ob/ob) mice.  Metabolism 50, 1402-1408, 2001.


  • Bailey CJ. Antidiabetic drugs. Brit J Cardiol 7, 350-360,2000.
  • Bailey CJ. Potential new treatments for type 2 diabetes. Trends in Pharmacol Sci 21, 259-265, 2000.
  • Bailey CJ. The rise and fall of troglitazone. Diabetic Med 17,414-415, 2000.
  • Bailey CJ. Rosiglitazone and pioglitazone: two new thiazolidinediones. Pract Diabetes Int 17, 135-137, 2000.
  • Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. Brit Med J 321, 252-253,2000.
  • Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. In Drug Treatment of Type 2 Diabetes, Krentz AJ (ed). Adis Int, Auckland, 2000, pp61-76.
  • Bailey CJ, Bates SH, Turner SL, Rossi M, Morgan I, Bloom SR.  Leptin improves insulin sensitivity of skeletal muscle in obese-diabetic ob/ob mice.  Pharm Pharmacol Comm 6, 35-39, 2000.
  • Wood MJ, Bailey CJ. Making a case for inclusion of new oral anti-diabetic agents in drug formularies.  Pract Diabetes Int 17, 141-146,2000.
  • Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Brit J Pharmacol 130, Bailey CJ.  Metformin: a useful adjunct to insulin therapy.  Diabetic Med 17, 83-84, 2000.
  • Bailey CJ, Feher MD. (2009). Diabetes therapies: treating hyperglycaemia.  Birmingham, MedEd UK.
  • Bailey CJ et al (eds) (2007) “Metformin:the gold standard” Wiley, Chichester.
  • Krentz AJ, Bailey CJ. (2005) “Type 2 Diabetes”, 2nd edition, London, Roy Soc Med Press.
  • Bailey CJ, Feher MD. (2004), “Therapies for diabetes”, Birmingham, SherborneGibbs.
  • Krentz AJ, Bailey CJ. (2001) “Type 2 Diabetes”, London, Roy Soc Med Press.
  • Bailey CJ, Flatt PR. (1990) “New Antidiabetic Drugs”, London, Smith-Gordon.

  • Co-author of Diabetes in Europe Policy Puzzle: The State We Are In, 4th Edition (2014)

  • Bailey CJ (2007) Oral antidiabetic drugs. Encyclopedic Reference of Molecular Pharmacology.2nd edn. 
    Offermans S, Rosenthal W (eds) Springer-Verlag, Heidelberg
  • Bailey CJ, Day C (2004) Biguanides, Metformin, Thiazolidinediones , Ciglitazone, Troglitazone, Pioglotazone, Rosiglitazone. 
    Enna SJ, Bylund DB, (eds) Elsevier, New York 
  • Bailey CJ (2003) Oral antidiabetic drugs, Encyclopedic Reference of Molecular Pharmacology.
    Offermans S, Rosenthal W (eds) Springer-Verlag, Heidelberg, 688-69.


Excellent Different Distinctive